AUA 2019: Diagnostic Efficacy of 18F-RHPSMA7 Positron Emission Tomography for N-staging of Patients with High Risk Primary Prostate Cancer

Chicago, IL ( Retrospective research study was conducted to evaluate 18F radio hybrid prostate specific membrane antigen positron emission tomography (18F-rhPSMA7 PET) for primary N-staging in prostate cancer patients. Previous studies demonstrate that 18F PSNA ligands are superior to the 68Ga- PSMA PET in relation to half-life, negligible urine secretion, and positron range. Further research was needed to estimate 18F-rhPSMA efficacy for the diagnosis of metastatic prostate cancer.

The study team reviewed 18F-rhPSMA PET/CT and PET/MRI scans of high-risk prostate cancer patients who underwent radical prostatectomy with extended pelvic lymph node dissections. Independent research radiologist reviewed images and rated them on a 5-point scale for the lymph node involvement. Original imaging findings were compared to the independent readings and surgical pathology results.

The patient cohort consisted of 58 participants with a median age of 68 years, and median PSA of 12.4 ng/ml at PET (Figure 1).


Data analysis showed that 31% of study participants had a lymph node involvement. Research demonstrated increased sensitivity (72.2%), specificity (92.5%), and accuracy (86.2%) of 18F-rhPSMA PET compared to the morphological imaging (50.0%, 72.5% and 65.5%) (Figure 2).


The study conducted an additional template-based analysis of the imaging, and 18F-rhPSMA PET succeeded indicators of morphological imaging in terms of sensitivity, specificity, and accuracy.

Research indicated that 18F-rhPSMA PET had more favorable parameters in diagnosing N-staging of prostate cancer compared to the commonly used 68Ga- PSMA PET.

Presented by: Tobias Maurer, MD, Researcher, Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Co-authors: Markus Kroenke,
Alexander Wurzer, Kristina Schwamborn, Lena Ulbrich, Lena Joo, Thomas Horn, Bernhard Haller, Wolfgang Weber, Hans-Jurgen Wester, Matthias Eiber, Munich, Germany

Written by: Hanna Stambakio, BS, Clinical Research Coordinator, Division of Urology, University of Pennsylvania Twitter: @AStambakio at the American Urological Association's 2019 Annual Meeting (AUA 2019), May 3 – 6, 2019 in Chicago, Illinois